...
首页> 外文期刊>Critical reviews in oncology/hematology >A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)
【24h】

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)

机译:保留膀胱的三联疗法治疗肌肉浸润性膀胱癌(MIBC)的临床试验的系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Despite the numerous prospective and retrospective studies published during the last 2 decades aiming at testing the safety and the efficacy of trimodality therapy (TMT) as a conservative treatment, an optimal therapeutic strategy has not yet been identified. We made a systematic overview of the 5-year outcomes from 31 trials of combined chemotherapy and radiation (CRT) after transurethral resection of muscle-infiltrating bladder tumours (TURBT), the so-called trimodality therapy. We took into consideration the results of each trial i.e. the rate of complete response (CR), local muscle-invasive local failure (LF), salvage cystectomy (SC), 5-year overall survival (OS) and 5-year bladder intact survival (BIS) from 3315 patients.
机译:目的:尽管在过去的20年中发表了许多前瞻性和回顾性研究,旨在测试三联疗法(TMT)作为保守疗法的安全性和有效性,但尚未确定最佳的治疗策略。我们对31项化学疗法和放疗(CRT)联合疗法(即所谓的三联疗法)经尿道肌肉浸润性膀胱切除术后的5年结局进行了系统综述。我们考虑了每个试验的结果,即完全缓解率(CR),局部肌肉浸润性局部衰竭(LF),挽救性膀胱切除术(SC),5年总体生存率(OS)和5年膀胱完整生存率(BIS)来自3315位患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号